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ABSTRACT
Daptomycin is the first in a new class of antibiotics, the cyclic lipopeptides. This review discusses the
extensive in vitro tests performed to characterise the antimicrobial activity of daptomycin. These tests
have established daptomycin’s activity against most Gram-positive bacteria, including methicillin-
sensitive and -resistant Staphylococcus aureus, vancomycin-resistant enterococci and multidrug-resistant
coagulase-negative staphylococci. Daptomycin possesses rapid, concentration-dependent bactericidal
activity against Gram-positive organisms. Interestingly, this in vitro bactericidal activity is maintained at
high inoculum densities and against bacteria in the stationary phase of growth. In addition, in vitro tests
have demonstrated a prolonged, concentration-dependent post-antibiotic effect against Gram-positive
bacteria. The level of protein binding of daptomycin is high. However, daptomycin binds only weakly to
albumin, and is two- to four-fold more active than would be predicted from its free drug concentration.
In vitro studies have shown low spontaneous resistance rates of <10)10 for S. aureus and <10)9 for
Staphylococcus epidermidis, Enterococcus faecalis and Enterococcus faecium. In summary, in vitro testing
clearly demonstrates that daptomycin is an exciting new option for the treatment of Gram-positive
infections.
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INTRODUCTION
Daptomycin was originally isolated as a fermen-
tation product of the soil-dwelling bacterium
Streptomyces roseosporus. This cyclic lipopeptide
antibiotic has recently been licensed in Europe for
the treatment of complicated skin and soft tissue
infections (cSSTIs) in adults. During the drug
development process and beyond, daptomycin
has undergone rigorous tests to establish and
characterise its antimicrobial activity. The objec-
tive of this article is to summarise and discuss the
results of these tests, with particular emphasis on
the most recent data describing the in vitro activity
of daptomycin, its bactericidal activity, protein
binding, activity in biofilms, post-antibiotic effect
(PAE), synergistic interactions with other antibi-
otics, and potential for resistance development.
STRUCTURE AND MODE OF ACTION
Daptomycin is a 13-amino-acid lipopeptide com-
prising a hydrophilic core and a lipophilic tail.
This unique structure confers upon daptomycin a
completely novel mode of action involving inser-
tion into the cytoplasmic membrane of Gram-
positive bacteria and the formation of daptomycin
pores. This Ca2+-dependent process leads to
efflux of cell components, particularly potassium
ions, and subsequent membrane depolarisation
and cell death. Daptomycin kills bacteria with
negligible cell lysis, so the theoretical risks asso-
ciated with bacterial cell lysis—including the
release of bacterial exotoxins into the circula-
tion—are potentially minimised [1,2]. The mode
of action of daptomycin has been described in
some detail elsewhere [2,3].
IN-VITRO ACTIVITY
Daptomycin is active in vitro against most Gram-
positive bacteria, including clinically important
drug-resistant pathogens such as methicillin-
resistant Staphylococcus aureus (MRSA), vanco-
mycin-resistant enterococci (VRE) and multi-
drug-resistant coagulase-negative staphylococci
[4–6]. This broad-ranging activity was confirmed
in a recent surveillance study involving the
collection of Gram-positive isolates from 24
medical centres in 12 European countries
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(H. Sader et al. ECCMID 2005). In this study,
daptomycin was shown to be active against
S. aureus and coagulase-negative staphylococci
with MIC90 values of 0.5 mg/L. In-vitro activity
against these pathogens was maintained irres-
pective of the presence or absence of methicillin
resistance.
MIC distribution data
While MIC50 and MIC90 data are undeniably
useful, the in-vitro activity of antibiotics such as
daptomycin can be described in more detail by
MIC distribution data. The concept of ‘antimicro-
bial wild-type susceptibility distributions’ has
been developed by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
[7]. Through its website (http://www.srga.org/
eucastwt/wt_eucast.htm), EUCAST displays
aggregate MIC distributions for numerous anti-
microbial–microorganism combinations. Each
aggregate is formed from individual MIC distri-
butions obtained from a variety of worldwide
sources, including peer-reviewed publications,
national breakpoint committees, pharmaceutical
companies and antimicrobial resistance surveil-
lance projects. Only wild-type distribution data
(i.e., data for bacteria without acquired resistance
to the antibiotic agent of interest) are available
from EUCAST.
Aggregate MIC distributions for daptomycin
against a range of Gram-positive bacteria are
shown in Table 1. For each bacterial species, peaks
of activity for daptomycin can be clearly seen.
Pathogens with particular sensitivity to daptomy-
cin identified from the EUCAST data include
Streptococcus pyogenes, Streptococcus agalactiae,
Streptococcus pneumoniae, S. aureus, S. epidermidis
and the coagulase-negative staphylococci.
Activity against glycopeptide-intermediate
and -resistant pathogens
The emergence of glycopeptide resistance in
S. aureus is a well-established and worrying phe-
nomenon. Although fully vancomycin-resistant
S. aureus (VRSA) organisms are rare, vancomycin-
intermediate strains are more common [8]. Dap-
tomycin has been shown to be active against
VRSA, vancomycin-intermediate S. aureus (VISA)
Table 1. MIC distributions for daptomycin [7]
MIC (mg/L)
0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16
Streptococcus pyogenes (n ¼ 825) 1 16 64 17 2 0 0 0 0 0 0
Streptococcus bovis (n ¼ 91) 2 5 62 29 2 0 0 0 0 0 0
Streptococcus group G (n ¼ 269) 0 11 61 25 3 0 0 0 0 0 0
Streptococcus agalactiae (n ¼ 1686) 0 0 21 48 26 4 0 0 0 0 0
Corynebacterium jeikeium (n ¼ 10) 0 0 30 60 10 0 0 0 0 0 0
Streptococcus pneumoniae (n ¼ 7661) 0 0 3 63 30 4 0 0 0 0 0
Clostridium species (n ¼ 68) 0 3 26 35 24 4 3 0 0 3 1
Staphylococcus hominis (n ¼ 192) 0 0 1 16 64 18 1 0 0 0 0
Streptococcus mitis (n ¼ 142) 0 1 3 8 37 35 17 0 0 0 0
Streptococcus viridans (n ¼ 659) 0 1 9 18 30 29 13 0 0 0 0
Staphylococcus aureus (n ¼ 35 965) 0 0 2 22 51 23 2 0 0 0 0
Staphylococcus epidermidis (n ¼ 1979) 0 0 2 9 47 40 3 0 0 0 0
Staphylococcus, coagulase-negative (n ¼ 8966) 0 0 7 27 42 21 2 0 0 0 0
Staphylococcus haemolyticus (n ¼ 258) 0 0 0 12 48 37 3 0 0 0 0
Staphylococcus capitis (n ¼ 30) 0 0 0 0 10 53 37 0 0 0 0
Streptococcus anginosus (n ¼ 22) 0 0 5 0 41 55 0 0 0 0 0
Streptococcus oralis (n ¼ 50) 0 0 0 8 20 44 28 0 0 0 0
Enterococcus faecalis (n ¼ 9435) 0 0 0 1 5 31 42 18 3 0 0
Enterococcus faecium (n ¼ 12 308) 0 0 0 0 0 1 6 84 8 0 0
Listeria monocytogenes (n ¼ 78) 0 0 0 0 1 1 33 54 10 0 0
For each MIC value, data represent the percentage of tested isolates (n) with an equivalent MIC value. Values in bold
represent the most common MIC for each species. For example, 64% of Streptococcus pyogenes isolates were associated with
a daptomycin MIC of 0.064 mg/L.
Data from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) website (2005).
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and other vancomycin-intermediate staphylococci
[9,10].
Recent reports have proposed a correlation
between reduced daptomycin susceptibility and
vancomycin resistance in MRSA isolates from
patients exposed to vancomycin, VISA and
S. aureus passaged in vancomycin-containing
medium [11,12]. However, neither of these
studies looked at minimum bactericidal concen-
trations. Tolerance of S. aureus to vancomycin is
common, while tolerance to daptomycin has not
yet been observed [13,14]. Therefore, it remains
to be clarified whether reports of reduced
susceptibility to daptomycin following exposure
to vancomycin represent true cross-resistance.
In-vitro testing methods
Consistent with the Ca2+-dependent mode of
action of daptomycin, in-vitro testing methods
require physiological concentrations of free cal-
cium ions (50 mg/L) [15]. Broth microdilution is
the ‘gold standard’ susceptibility testing method
for daptomycin, and E-test methods are also
reliable. Agar dilution methods are not recom-
mended—Ca2+ levels in agar vary and dapto-
mycin does not diffuse easily through agar.
Daptomycin has a high molecular mass
(1620 Da); all antibiotics with a molecular mass
over approximately 700 Da have poor diffusion
characteristics from paper disks into the surface
agar (e.g., teicoplanin, 1993 Da) [15]. Disk diffu-
sion methods are not available for susceptibility
testing with daptomycin.
Daptomycin panels and cards are available for
use with several automated and semi-automated
susceptibility testing systems [15]. The following
daptomycin MIC breakpoints have been estab-
lished by EUCAST for both staphylococci and
streptococci (excluding Streptococcus pneumoniae):
£1 mg/L (susceptible) and >1 mg/L (resistant)
[16].
BACTERICIDAL ACTIVITY
Bactericidal antibiotic agents offer potential
advantages over bacteriostatic agents, including
the potential suppression of resistance selection
and rapid bactericidal effects that are independ-
ent of the host immune response [17,18]. In-vitro
time-kill studies have shown that daptomycin
possesses rapid, concentration-dependent bacte-
ricidal activity against Gram-positive organisms
[4,19]. For example, daptomycin has been shown
to reduce S. aureus viable cell counts (including
MRSA) by more than three orders of magnitude
in <2 h at concentrations two to four times the
MIC [19].
The bactericidal activity of daptomycin is
reduced only slightly by an increase in inoculum
density. In an in-vitro study utilising simulated
bacterial vegetations, daptomycin retained its
bactericidal activity against both moderate- and
high-density MRSA and methicillin-susceptible
S. aureus (MSSA) inocula [20]. In contrast, no
reduction in cell counts was seen at either inocu-
lum density with the bacteriostatic agent linezo-
lid, while the bactericidal activities of nafcillin
and vancomycin were greatly diminished at high
inoculum densities.
The bactericidal activity of daptomycin is also
maintained in the stationary phase of bacterial
growth [21]. In a recent study, the in-vivo bacte-
ricidal activity of daptomycin, unlike those of
ciprofloxacin and nafcillin, was maintained
against cold-arrested, non-growing S. aureus (C.
Mascio et al. ICAAC 2005).
PROTEIN BINDING
Pharmacokinetic studies have shown that dapto-
mycin binds reversibly to human plasma proteins,
primarily albumin, in a concentration-dependent
manner [22]. Although the level of protein binding
is high (90% at 4 g/100 mL), daptomycin binds
only weakly to albumin and daptomycin is two- to
four-fold more active than would be predicted
from its free drug concentration (W. Craig et al.
IDSA 2004). Further evidence for weak and/or
highly reversible protein binding was provided in
a recent in-vitro study demonstrating only min-
imal effects of human serum on the bactericidal
activity of daptomycin (I. Morissey et al. ECCMID
2006). In this study, exponentially growing MSSA,
MRSA, vancomycin-susceptible Enterococcus fae-
cium and VRE were exposed to daptomycin,
vancomycin, teicoplanin, piperacillin–tazobactam
or linezolid in the presence and absence of 50%
human serum. To compare the bactericidal activ-
ities of each antibiotic agent, bactericidal indices
were calculated by plotting the log reduction in
viable cell counts over time and measuring the
resulting area-under-the-curve. With or without
the addition of human serum, daptomycin was
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the most bactericidal agent; however, the serum
concentration used was far greater than physio-
logical levels.
ACTIVITY IN BIOFILMS
Biofilms are extracellular matrices that allow
bacteria to accumulate at high densities. By
acting as a physical barrier to antibiotics, and
through other mechanisms, biofilms may pre-
vent effective treatment and/or promote the
development of antibiotic resistance. Raad et al.
evaluated the activity of daptomycin, linezolid,
minocycline and quinupristin–dalfopristin
against bacteria in biofilms generated from
vancomycin-resistant E. faecium isolates from
patients with catheter-related bacteraemia [23].
While the colonisation densities of linezolid-
treated and control water-treated biofilms were
comparable, daptomycin produced an approxi-
mately 97% reduction in the number of CFUs
(Fig. 1). Daptomycin was the most effective
antibiotic tested, producing a greater reduction
in the number of E. faecium CFUs than minocy-
cline, quinupristin–dalfopristin and linezolid. At
a simulated dose of 6 mg/kg, daptomycin also
demonstrated potent bactericidal activity in vivo
against implanted endocardial MRSA vegeta-
tions in rats (L. Mortin et al. American Society
for Microbiology 2003). The activity in biofilms
of daptomycin and other antibiotic agents is an
important area for future research.
POST-ANTIBIOTIC EFFECT AND
SYNERGY
The maintained suppression of bacterial growth
following exposure to an antibiotic is referred to
as the post-antibiotic effect (PAE). Although their
clinical significance has not been fully deter-
mined, prolonged PAEs measured in vitro may
indicate the suppression of bacterial growth
in vivo during periods of low drug concentration
[24]. In-vitro experiments with daptomycin have
revealed a prolonged, concentration-dependent
PAE against Gram-positive bacteria [25,26]. Han-
berger et al. measured the PAE of daptomycin
using viable cell counts and a bioluminescence
assay of bacterial ATP [25]. At clinically achiev-
able concentrations, and in the presence of
physiological levels of free Ca2+, daptomycin
produced a PAE of over 6 h against Enterococcus
faecalis and S. aureus.
Synergistic interactions between daptomycin
and some other antibiotics have been demonstra-
ted in vitro. For example, both rifampicin and
ampicillin show synergistic activity with dapto-
mycin against VRE [27,28]. Importantly, antagon-
istic activity following combination of
daptomycin with other antibiotics has not been
reported.
RESISTANCE
The development of antibiotic resistance is a
complex process and first requires the presence
of a gene complex mediating resistance to an
antibiotic agent (Fig. 2). Either by mutation or by
uptake of resistance plasmids, this gene complex
must enter the genome of a suitable pathogen.
Selection pressure must then favour the drug-
resistant pathogen. Providing that it is able to
survive in its specific ecosystem, the drug-resist-
ant pathogen may then be able to spread to the
wider environment.
In-vitro resistance
Studies have shown that daptomycin has low
potential for the development of resistance in vitro.
Silverman et al. found no spontaneous resistant
mutants among organisms exposed to daptomy-
cin at eight times the MIC; resulting spontaneous
mutation rates were <10)10 for S. aureus and <10)9
for S. epidermidis, E. faecalis, E. faecium and
Fig. 1. Activity of daptomycin and other antibiotics in
biofilms. The activity of daptomycin (DAP), minocycline
(MIN), quinupristin–dalfopristin (Q-D) and linezolid (LIN)
was tested against bacteria in biofilms generated from
vancomycin-resistant Enterococcus faecium isolates obtained
from patients with catheter-related bacteraemia. Data
represent the reduction in number of CFUs measured
following the addition of each antibiotic. Adapted from
Raad et al. 2005 [23].
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Streptococcus pneumoniae [29]. In the same study,
daptomycin-resistant isolates were difficult to
select by serial passage—requiring over 20 pas-
sages—and were infrequently selected by chem-
ical mutagenesis. Consistent with the novel mode
of action of daptomycin, none of the daptomycin-
resistant isolates were cross-resistant to vanco-
mycin or ampicillin.
In-vivo resistance
The low potential for resistance in vitro is reflected
by the low incidence of daptomycin resistance in
the clinical setting. More than 1000 patients were
treated with daptomycin during phase II and III
studies, and resistance emerged in just two of
these patients (<0.2%) [16,30]. Since it was
launched in the USA in September 2003, more
than 120 000 patients have been treated with
daptomycin; resistance to daptomycin has been
reported in 13 patients (S. aureus, n ¼ 8; E. fae-
cium, n ¼ 4; E. faecalis, n ¼ 1). In all 13 cases,
patients had bacteraemia with osteomyelitis,
endocarditis and/or concurrent immunosuppres-
sion. There have been no post-marketing reports
of daptomycin-resistant isolates in patients trea-
ted for cSSTIs.
The safety and efficacy of daptomycin for
the treatment of S. aureus endocarditis and/or
bacteraemia was assessed in a recent phase III
clinical study [31]. In this study, daptomycin
MICs crept above the CLSI breakpoint (1 mg/L)
in seven patients. All of these patients had deep-
seated infections that required adjunctive therapy
(e.g., valve surgery, drainage of infection foci,
removal of foreign material). Six patients—none
of whom received the required adjunctive ther-
apy—had persisting or relapsing infection. The
seventh patient received adjunctive therapy and
was considered a clinical success.
SUMMARY
Extensive testing has shown that daptomycin
possesses rapid bactericidal activity against a
broad range of Gram-positive bacteria. This activ-
ity is maintained against both high inocula and
non-growing bacterial cells. Daptomycin has a
prolonged PAE and shows synergy with certain
other antibiotic agents. The potential to induce
daptomycin-resistant mutants in vitro is low, and
resistant isolates have only rarely been recovered
from daptomycin-treated patients. Interesting
areas for future testing include further character-
isation of daptomycin’s mode of action, its protein
binding and its activity in biofilms. It is already
clear, however, that daptomycin represents an
exciting new option for the treatment of Gram-
positive infections.
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